PMC:7461420 / 53454-54276
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T235 | 646-652 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T236 | 762-768 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T237 | 806-812 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T238 | 813-821 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T259 | 35-39 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T260 | 55-59 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T261 | 193-197 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T262 | 306-310 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T263 | 378-382 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T264 | 450-454 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T676 | 128-133 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T677 | 191-192 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T678 | 399-400 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T679 | 471-472 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T680 | 592-594 | http://purl.obolibrary.org/obo/CLO_0008307 | denotes | P2 |
T681 | 646-652 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T682 | 762-768 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T683 | 806-812 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T7603 | 179-187 | Chemical | denotes | molecule | http://purl.obolibrary.org/obo/CHEBI_25367 |
T40736 | 204-218 | Chemical | denotes | Mpro inhibitor | http://purl.obolibrary.org/obo/CHEBI_147285 |
T97159 | 209-218 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T77172 | 592-594 | Chemical | denotes | P2 | http://purl.obolibrary.org/obo/CHEBI_33472 |
T56473 | 598-603 | Chemical | denotes | amide | http://purl.obolibrary.org/obo/CHEBI_29337|http://purl.obolibrary.org/obo/CHEBI_32988 |
T64629 | 618-626 | Chemical | denotes | pyridone | http://purl.obolibrary.org/obo/CHEBI_38183 |
T15402 | 736-745 | Chemical | denotes | Boc group | http://purl.obolibrary.org/obo/CHEBI_48502 |
T58006 | 740-745 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
T93511 | 813-821 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1625 | 204-208 | Gene | denotes | Mpro | Gene:8673700 |
1626 | 461-465 | Gene | denotes | Mpro | Gene:8673700 |
1627 | 389-393 | Gene | denotes | Mpro | Gene:8673700 |
1628 | 317-321 | Gene | denotes | Mpro | Gene:8673700 |
1629 | 66-70 | Gene | denotes | Mpro | Gene:8673700 |
1630 | 46-50 | Gene | denotes | Mpro | Gene:8673700 |
1631 | 35-43 | Species | denotes | SARS‐CoV | Tax:694009 |
1632 | 55-65 | Species | denotes | SARS‐CoV‐2 | Tax:2697049 |
1633 | 193-203 | Species | denotes | SARS‐CoV‐2 | Tax:2697049 |
1634 | 306-316 | Species | denotes | SARS‐CoV‐2 | Tax:2697049 |
1635 | 378-386 | Species | denotes | SARS‐CoV | Tax:694009 |
1636 | 450-460 | Species | denotes | SARS‐CoV‐2 | Tax:2697049 |
1637 | 592-594 | Chemical | denotes | P2 | MESH:C020845 |
1638 | 598-603 | Chemical | denotes | amide | MESH:D000577 |
1639 | 618-626 | Chemical | denotes | pyridone | MESH:D011728 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T473 | 0-142 | Sentence | denotes | Due to the high similarity between SARS‐CoV‐1 Mpro and SARS‐CoV‐2 Mpro authors speculated that 64 was likely to inhibit the new virus as well. |
T474 | 143-249 | Sentence | denotes | Zhang et al. recently reported this molecule as a SARS‐CoV‐2 Mpro inhibitor with an IC50 value of 0.18 µM. |
T475 | 250-423 | Sentence | denotes | They first resolved the unliganded crystal structure of SARS‐CoV‐2 Mpro (Figure 20), 157 which is largely identical to that of SARS‐CoV‐1 Mpro with a 96% sequence identity. |
T476 | 424-565 | Sentence | denotes | Compound 64 was docked to SARS‐CoV‐2 Mpro, and a series of structural modifications were performed to improve its pharmacokinetic properties. |
T477 | 566-822 | Sentence | denotes | Specifically, masking the P2‐P3 amide bond with the pyridone ring could improve plasma half‐life; and exchanging the lipophilic cinnamoyl residue for the less lipophilic Boc group, could increase plasma solubility and reduce its binding to plasma proteins. |